戻る
AnaptysBio Inc (ANAB)価格
ANAB 株価推移チャート
ANAB 収入
AnaptysBio Inc
$45.68
-1.36%
$-0.63
終値： Jan 16, 16:00:00 GMT-5
$44.61
-2.34%
$-1.07
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$46.31
始値
$46.51
当日レンジ
$44.61 - $47.54
52週レンジ
$12.21 - $52.47
取引高
356.9K
平均取引高
547.7K
1株当たり利益(TTM)
-2.82
配当利回り
--
時価総額
$1.2B
ANABとは何ですか？
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.